Materials • Major Chemicals
$34.37 ▲ +2.08
(+6.44%)
MKT CAP: $4.12B • VOL: 4.04M
52W L $26 52W H $41
VVV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.71B | $1.62B | $1.44B |
| YoY Revenue Growth % | +5.6% | +12.2% | — |
| Gross Profit | $658.5M | $618.8M | — |
| Gross Margin % | 38.5% | 38.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $389.9M | $367.2M | $247.2M |
| Operating Margin % | 22.8% | 22.7% | 17.1% |
| Net Income (GAAP) | $210.7M | $211.5M | $1.42B |
| EBITDA (Normalized) | $597.3M | $546.7M | $299.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $297.2M | $265.1M | -$40.8M |
| Capital Expenditures (CapEx) | $259.2M | $224.4M | $65.0M |
| Free Cash Flow (FCF) | $38.0M | $40.7M | -$105.8M |
| FCF Margin % | 2.2% | 2.5% | -7.3% |
| Return on Invested Capital (ROIC %) | 16.5% | 24.6% | 14.2% |
| Cash & Short-Term Equivalents | $69.9M | $60.0M | — |
| Total Debt (Short + Long Term) | $1.63B | $1.01B | $531.7M |
| Total Stockholders' Equity | $307.6M | $229.8M | $1.09B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VVV.